We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Genmab A S
9 own
6 watching
Current Price
$20.47
$-0.29
(-1.4%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
118.84M
52-Week High
32.88000
52-Week Low
19.85000
Average Volume
0.45M
Dividend Yield
--
P/E Ratio
13.3069
Market Capitalization118.84M52-Week High32.8800052-Week Low19.85000Average Volume0.45MDividend Yield--P/E Ratio13.3069What does the Genmab A S do?
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; a research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Read More
News & Events about Genmab A S.
Business Wire
1 year ago
Genmab A/S (Nasdaq: GMAB) today announced data from its ongoing phase 1/2 EPCORE NHL-2 trial investigating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab-lenalidomide (R2) showed an overall response rate (ORR) of 98 percent and complete...
Globe Newswire
1 year ago
Media ReleaseCOPENHAGEN, Denmark; June 9, 2023, at 9:00am CEST Results from phase 1/2 EPCORE NHL-2 trial investigating epcoritamab in combination with rituximab-lenalidomide (R2) showed a 98 percent overall response rate (ORR), 87 percent complete metabolic response (CMR) in patients with relapsed ...
Globe Newswire
1 year ago
Company Announcement COPENHAGEN, Denmark; April 24, 2023 Genmab A/S (Nasdaq: GMAB) announced today its decision to file a request for review of the award dismissing its claims in the second arbitration arising under its license agreement with Janssen Biotech, Inc. for daratumumab. The review of the ...
Globe Newswire
1 year ago
Genmabandargenxhave entered into a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies Discovery programs against two differentiated targets are underway Amsterdam, the Netherlands 04/17/2023 argenx SE (Euronext & Nasdaq: ARGX) and...
Globe Newswire
1 year ago
Media ReleaseCOPENHAGEN, Denmark; April 17, 2023 Genmabandargenxhave entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapiesDiscovery programs against two differentiated targets are underway GenmabA/S(Nasdaq:GMAB) andargenx(...
Frequently Asked Questions
Frequently Asked Questions
What is Genmab A S share price today?
Can Indians buy Genmab A S shares?
How can I buy Genmab A S shares from India?
Can Fractional shares of Genmab A S be purchased?
What are the documents required to start investing in Genmab A S stocks?
What is today’s traded volume of Genmab A S?
What is today’s market capitalisation of Genmab A S?
What is the 52-Week High and Low Range of Genmab A S?
What percentage is Genmab A S down from its 52-Week High?
What percentage is Genmab A S up from its 52-Week Low?
Current Price
$20.47
$-0.29
(-1.4%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.